|
Jun 23
|
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
|
|
Jun 18
|
Nuvalent Appoints Christy Oliger to Board of Directors
|
|
Feb 11
|
Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently
|
|
Jan 20
|
Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
|
|
Dec 30
|
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls
|
|
Dec 19
|
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Dec 9
|
Nuvalent Appoints Grant Bogle to Board of Directors
|
|
Sep 19
|
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
|
|
Sep 18
|
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
|
|
Sep 18
|
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
|
|
Sep 17
|
Company News for Sep 17, 2024
|
|
Sep 17
|
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
|
|
Sep 16
|
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
|
|
Sep 16
|
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data
|
|
Sep 16
|
Nuvalent Announces Public Offering of Common Stock
|
|
Sep 14
|
Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks
|
|
Sep 14
|
Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
|
|
Sep 14
|
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
|
|
Sep 13
|
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
|
|
May 9
|
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
|